Cargando…

Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease

BACKGROUND: Since the Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups A–D were introduced, the lung function changes according to group have been evaluated rarely. OBJECTIVE: We investigated the rate of decline in annual lung function in patients categorized according to the 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joohae, Yoon, Ho Il, Oh, Yeon-Mok, Lim, Seong Yong, Lee, Ji-Hyun, Kim, Tae-Hyung, Lee, Sang Yeub, Lee, Jin Hwa, Lee, Sang-Do, Lee, Chang-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567243/
https://www.ncbi.nlm.nih.gov/pubmed/26379432
http://dx.doi.org/10.2147/COPD.S87766
Descripción
Sumario:BACKGROUND: Since the Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups A–D were introduced, the lung function changes according to group have been evaluated rarely. OBJECTIVE: We investigated the rate of decline in annual lung function in patients categorized according to the 2014 GOLD guidelines. METHODS: Patients with COPD included in the Korean Obstructive Lung Disease (KOLD) prospective study, who underwent yearly postbronchodilator spirometry at least three times, were included. The main outcome was the annual decline in postbronchodilator forced expiratory volume in 1 second (FEV(1)), which was analyzed by random-slope and random-intercept mixed linear regression. RESULTS: A total 175 participants were included. No significant postbronchodilator FEV(1) decline was observed between the groups (−34.4±7.9 [group A]; −26.2±9.4 [group B]; −22.7±16.0 [group C]; and −24.0±8.7 mL/year [group D]) (P=0.79). The group with less symptoms (−32.3±7.2 vs −25.0±6.5 mL/year) (P=0.44) and the low risk group (−31.0±6.1 vs −23.6±7.7 mL/year) (P=0.44) at baseline showed a more rapid decline in the postbronchodilator FEV(1), but the trends were not statistically significant. However, GOLD stages classified by FEV(1) were significantly related to the annual lung function decline. CONCLUSION: There was no significant difference in lung function decline rates according to the GOLD groups. Prior classification using postbronchodilator FEV(1) predicts decline in lung function better than does the new classification.